Research and development agreement

Titan Medical Reports Operating and Financial Results for the Fourth Quarter and Year End 2022 and Announces Availability of Materials for the 2023 Annual Meeting of Shareholders

Retrieved on: 
Thursday, June 1, 2023
Research and development agreement, Computershare, LLP, Intellectual property, TMD, Bank statement, Telephone, Medtronic, Dragon, Dragon (magazine), G&A, Research, Meeting, Holiday, RAS, CFO, TSX, R, Remuneration, Retail, Cryptocurrency, Titan

The Company also announced that its 2023 annual meeting (the “Meeting”) is scheduled for Friday, June 30, 2023 at 4:00 pm E.T.

Key Points: 
  • The Company also announced that its 2023 annual meeting (the “Meeting”) is scheduled for Friday, June 30, 2023 at 4:00 pm E.T.
  • Note that the financial review below discusses the business as of December 31st, 2022.
  • As part of the Strategic Review and as previously disclosed, the Company significantly reduced all operating expenses commencing in late 2022 and through-out 2023 to date.
  • As of December 31, 2022, Titan had cash of $3.3 million, compared to $32.3 million at December 31, 2021.

Teako Minerals Announces Strategic Partnership with The Coring Company - a Norwegian Technology Company

Retrieved on: 
Wednesday, April 19, 2023
Partnership, CSE, Sale, Government, Coring, Research and development agreement, Development, TCC, Party, Mining, AI, Research, Robotics, SCS, Innovation Norway

Vancouver, British Columbia--(Newsfile Corp. - April 19, 2023) - TEAKO MINERALS CORP. (CSE: TMIN) (the "Company" or "Teako"), is pleased to announce a strategic partnership with The Coring Company AS ("TCC"), a fast-growing technology company that is creating a new standard for ground investigations using state-of-the-art research, AI, and robotics.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - April 19, 2023) - TEAKO MINERALS CORP. (CSE: TMIN) (the "Company" or "Teako"), is pleased to announce a strategic partnership with The Coring Company AS ("TCC"), a fast-growing technology company that is creating a new standard for ground investigations using state-of-the-art research, AI, and robotics.
  • TCC is a private company based in Norway that is arms' length to Teako.
  • Frida Vonstad, CEO of The Coring Company comments, "The mining industry is an important factor in the world's green transition.
  • Through combining The Coring Company's knowledge of technology with Teako's industry knowledge and network - the full potential of our innovative solutions can be reached.

Planet Based Foods Announces Development Agreement with Global Producer Döhler

Retrieved on: 
Tuesday, April 18, 2023
Social responsibility, Taste, Allergy, Food, CSE, Partnership, Research, Fruit, Dicarboxylic acid, FRA, B2C, Milk, Soy milk, Development, Risk, Lactose intolerance, Research and development agreement, Coffee, Ideation, Acid, Growth, Health, Isoflavone, Dairy, Dietary supplement, EU

VANCOUVER, BC, April 18, 2023 /PRNewswire/ - Planet Based Foods Global Inc. (CSE: PBF) (OTCQB: PBFFF) (FRA: AZ0) ("PBFG," "Planet Based Foods" or the "Company") is pleased to announce that the Company has entered into a non-exclusive development agreement ("Development Agreement") with renowned global producer, DoehlerGroup ("Doehler").

Key Points: 
  • VANCOUVER, BC, April 18, 2023 /PRNewswire/ - Planet Based Foods Global Inc. (CSE: PBF) (OTCQB: PBFFF) (FRA: AZ0) ("PBFG," "Planet Based Foods" or the "Company") is pleased to announce that the Company has entered into a non-exclusive development agreement ("Development Agreement") with renowned global producer, DoehlerGroup ("Doehler").
  • The objective of the Development Agreement is to establish a commercial relationship between Planet Based Foods and Doehler, with the intention to work towards a formal production agreement.
  • Developing and producing a cold brew coffee beverage using a hemp (and possibly oat) milk base alongside Planet Based Foods.
  • Doehler is a global producer, marketer, and supplier of natural ingredients, ingredient systems, and integrated solutions for the food and beverage industry.

TechLink Study Highlights Opportunities for Faster, More Profitable Innovation in Manufacturing, High-Tech

Retrieved on: 
Monday, February 27, 2023
Software, Research, Contracts, Technology, Defense, Science, Biotechnology, Aerospace, Manufacturing, Veterans, Health, Military, Technology transfer, United States Department of Veterans Affairs, U.S. Department of Defense Strategy for Operating in Cyberspace, Hasselt, MPI, Veteran, IndustryWeek, Government, Cooperative research and development agreement, University, Cooperative, Research and development agreement, Executive summary, Risk management, Creative industries, Fine chemical

With an uncertain market and access to capital shrinking, companies must find ways to launch and improve products with tighter budgets and timelines.

Key Points: 
  • With an uncertain market and access to capital shrinking, companies must find ways to launch and improve products with tighter budgets and timelines.
  • TechLink’s study shows an opportunity for U.S. companies to leverage innovation best practices that could open market opportunities and positively impact their bottom lines.
  • “This study offers insights into innovation opportunities and challenges familiar to TechLink,” says Austin Leach, TechLink’s Associate Director.
  • Half of companies see customers as key allies in innovation — but there’s untapped opportunity in universities and government labs.

Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems

Retrieved on: 
Monday, January 9, 2023
Cloud, United States Department of Veterans Affairs, VistA, Cooperative, GSA, Research and development agreement, SALT, Ecosystem, Information technology, Development, Cerner, Information technology architecture, Government, CRADA, Risk assessment, Version, Department of Defence, Hampton VAMC National Cemetery, Manchester VA Medical Center, Recognition, Veterans Health Administration, Kidney disease, CKD, Chronic kidney disease, Patient, General Services Administration, OIT, St. Cloud VA Health Care System, DKD, CPRS, United States Department of Defense, LSE, VHA, Hospital, Pharmaceutical industry, Veteran

LONDON and SALT LAKE CITY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the execution of a Co-operative Research and Development Agreement (CRADA) with the U.S. Veterans Health Administration Innovation Ecosystem (VHA IE) to install the KidneyIntelX solution inside the VA Health System’s Cloud Infrastructure and interface it with the VA Electronic Health Record Systems.

Key Points: 
  • LONDON and SALT LAKE CITY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the execution of a Co-operative Research and Development Agreement (CRADA) with the U.S. Veterans Health Administration Innovation Ecosystem (VHA IE) to install the KidneyIntelX solution inside the VA Health System’s Cloud Infrastructure and interface it with the VA Electronic Health Record Systems.
  • By installing the KidneyIntelX platform inside the VA infrastructure through this innovative approach, one of the first such implementations by the VA, the stringent requirements for the security of Veteran’s health information and data will be assured.
  • According to the March 17, 2020, Veterans Health Administration (VHA) Directive 1053, approximately 960,000 Veterans, or 11%, meet the established criteria for chronic kidney disease (CKD).
  • However, less than half of those Veterans, 320,000, or 5%, have been formally diagnosed with CKD.

Titan Medical Reports Financial Results for the Third Quarter 2022, and Announces Special Shareholder Meeting

Retrieved on: 
Thursday, November 10, 2022
Vance, GLOBE, Forward-looking statement, Marketing, TMD, Food, Research and development agreement, Webcast, RAS, Intention, Development, Classification, IDE, Investor relations, Regulation of tobacco by the U.S. Food and Drug Administration, R, Enos, News, Compliance, Time, Software, Company, Conference, Engineering, De novo, Medtronic, Surgeon, TSX, Growth, CEO, Motion, FDA, Trial of the century, Medical device, Risk management, Nasdaq, Titan, G&A

Titan is completing the final steps prior to the anticipated delivery of the first Enos system to its Chapel Hill facility before year-end 2022.

Key Points: 
  • Titan is completing the final steps prior to the anticipated delivery of the first Enos system to its Chapel Hill facility before year-end 2022.
  • Following submission, we expect to finalize our clinical trial design and continue to plan our commercialization strategy for the U.S. market.
  • Vance added, After careful consideration, the company has also decided to propose a consolidation of common shares to its shareholders.
  • ET today (November 10, 2022) to discuss the companys financial results for the three months ended September 30, 2022, and recent business highlights.

NASA Goddard Space Flight Center Awards Contract to SpaceLink for Technology Demonstration

Retrieved on: 
Tuesday, October 11, 2022
Time, Orbit, MEO, Development, CIS, NASA, Communes of Burundi, Goddard Space Flight Center, TDRSS, Multimedia, Spacecraft, San Francisco Bay Area, AWS, Research and development agreement, Mojave Air and Space Port, Awareness, Research, United States Army Space and Missile Defense Command, Gateway, DARPA, Mojave Desert, Direct, GSFC, Silicon, Amazon Web Services, Solution, View, Communications satellite

MCLEAN, Va., Oct. 11, 2022 /PRNewswire/ -- SpaceLink,  a company that provides secure data relay from any orbit, any time, announced it was awarded a contract by NASA Goddard Space Flight Center (GSFC) to study how commercial optical ground terminals will integrate into the Near Space Network. The funded study includes a demonstration of end-to-end transport of multi-source data at the SpaceLink gateway in the Mojave Desert.

Key Points: 
  • MCLEAN, Va., Oct. 11, 2022 /PRNewswire/ -- SpaceLink , a company that provides secure data relay from any orbit, any time, announced it was awarded a contract by NASA Goddard Space Flight Center (GSFC) to study how commercial optical ground terminals will integrate into the Near Space Network .
  • The funded study includes a demonstration of end-to-end transport of multi-source data at the SpaceLink gateway in the Mojave Desert.
  • "SpaceLink is excited to explore innovative solutions that can help inform and guide NASA towards the successful commercialization of the Near Space Network services."
  • "SpaceLink has demonstrated current and state of the art experience and technologies for space-based optical communication link and services," said Dr. Ruma Das, CIS Deputy Office Chief at NASA Goddard Space Flight Center.

Titan Medical Reports Financial Results for the First Quarter 2022

Retrieved on: 
Thursday, May 12, 2022
Biotechnology, Health, Surgery, Medical Devices, Benchmark, R, Research and development agreement, Regulation of tobacco by the U.S. Food and Drug Administration, Food, TMD, De novo, Nasdaq, Surgeon, Enos, Webcast, News, RAS, Investor relations, Marketing, Trial of the century, TSX, FDA, Intention, Conference, Forward-looking statement, Compliance, IDE, Motion, Adoption, Growth, Development, Chairperson, Classification, Interim, CEO, 3D printing, Risk management, Pharmaceutical industry, Online gambling, G&A, Titan, Medtronic

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three months ended March 31, 2022.

Key Points: 
  • Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three months ended March 31, 2022.
  • The company remains on track with the De Novo regulatory process for marketing authorization with the U.S. Food and Drug Administration (FDA).
  • Following IDE approval, Titan expects the IDE clinical study to proceed and be completed in time for submission of a De Novo classification request in 2024.
  • ET today (May 12, 2022) to discuss the companys financial results for the three months ended March 31, 2022, and recent business highlights.

Titan Medical Reports Operating and Financial Results for the Fourth Quarter and Year End 2021

Retrieved on: 
Thursday, March 24, 2022
Biotechnology, FDA, Surgery, Medical Devices, Health, Business development, IDE, Classification, Interim, Trial of the century, Marketing, Forward-looking statement, Society, Growth, Patient, Enos, Compliance, Research, Investor relations, Medtronic, Conference, Webcast, Motion, CEO, Food, TSX, Artificial intelligence, Society of American Gastrointestinal and Endoscopic Surgeons, Intention, Surgeon, De novo, Nasdaq, Machine learning, Regulation of tobacco by the U.S. Food and Drug Administration, RAS, Research and development agreement, News, R, Development, FDA, TMD, 3D printing, Video game, Medical device, Pharmaceutical industry, Online gambling, Lithium, Titan, G&A

Following IDE approval, the company expects to start the IDE human clinical study in the second half of 2023.

Key Points: 
  • Following IDE approval, the company expects to start the IDE human clinical study in the second half of 2023.
  • Commercial launch of the Enos system will begin upon receipt of marketing authorization from the FDA, anticipated in early 2025.
  • As of December 31, 2021, Titan had cash and cash equivalents of $32.3 million, compared to $25.5 million at December 31, 2020.
  • ET today (March 24, 2022) to discuss the companys financial results for the three and twelve months ended December 31, 2021, and recent business highlights.

Arizona Sonoran Completes Rezoning of Acquired Land

Retrieved on: 
Wednesday, January 5, 2022
Public Policy, Government, Natural Resources, State, Local, Mining, Minerals, City council, The Council, City, Failure, Mining, Company, Par value, Forward-looking statement, Metal, Community, Accident, Research and development agreement, Council, CASA, TSX, Comprehensive planning, Cactus, LKY, ASCU, Terrorism, Board, Commerce, News, Employment, ASARCO, Industry, PAD, Nagoya University of Commerce & Business, Renewable energy, Risk management

The Companys entire land package consists of 4,698 acres of private land sufficient to accommodate all the infrastructure envisioned within its 18-year Life-of-Mine Operating Plan.

Key Points: 
  • The Companys entire land package consists of 4,698 acres of private land sufficient to accommodate all the infrastructure envisioned within its 18-year Life-of-Mine Operating Plan.
  • Ian McMullan, ASCU COO commented, The rezoning marks our 6th major permit received in the permitting process of the Cactus Mine.
  • As a private landowner in Casa Grande, Arizona, we benefit from a streamlined permitting process at the state and county level.
  • Additionally, the land use designation (rezoning) (number 1178.414) is amended from commerce & business and residential to manufacturing/industrial use for the 2,159-acre parcel.